Cas No.: | 858747-13-4 |
Chemical Name: | {7-[(3-Bromobenzyl)oxy]-4,8-dimethyl-2-oxo-2H-chromen-3-yl}acetic acid |
Synonyms: | {7-[(3-bromobenzyl)oxy]-4,8-dimethyl-2-oxo-2H-chromen-3-yl}acetic acid;2-(7-((3-Bromobenzyl)oxy)-4,8-dimethyl-2-oxo-2H-chromen-3-yl)acetic acid;BDBM50519206;STL460018 |
SMILES: | BrC1=CC=CC(=C1)COC1C=CC2=C(C=1C)OC(C(CC(=O)O)=C2C)=O |
Formula: | C20H17BrO5 |
M.Wt: | 417.249985456467 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | DRAinh-A250 is a specific inhibitor of Cl-/anion exchanger SLC26A3 (DRA), fully and reversibly inhibits SLC26A3-mediated Cl- exchange with HCO3-, I-, and thiocyanate (SCN-) with IC50 of ~0.2 uM; does not inhibit the homologous anion exchangers SLC26A4 (pendrin) or SLC26A6 (PAT-1), as well as other related proteins or intestinal ion channels; blocked fluid absorption in closed colonic loops but not in jejunal loops in mice, while the NHE3 (SLC9A3) inhibitor tenapanor blocked absorption only in the jejunum; reduces signs of constipation in loperamide-treated mice after oral treatment. |